A Phase 3 registrational trial evaluating MHB018A
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs MHB-018A (Primary)
- Indications Graves ophthalmopathy
- Focus Registrational; Therapeutic Use
- 24 Oct 2024 New trial record
- 22 Oct 2024 According to Minghui Pharmaceutical Inc media release , company plans to initiate this trial in the first half of 2025